Editorial : Cholesterol and cancer drug resistance : molecular, signaling, and therapeutic aspects
- UPSpace Home
- →
- Health Sciences
- →
- Medical Oncology
- →
- Research Articles (Medical Oncology)
- →
- View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Kaur, Mandeep
|
|
| dc.contributor.author | Dlamini, Zodwa
|
|
| dc.date.accessioned | 2022-11-01T11:06:01Z | |
| dc.date.available | 2022-11-01T11:06:01Z | |
| dc.date.issued | 2022-09-15 | |
| dc.description.abstract | No abstract available. | en_US |
| dc.description.department | Medical Oncology | en_US |
| dc.description.librarian | dm2022 | en_US |
| dc.description.sponsorship | The National Research Foundation (NRF) and the the South African Medical Research Council- Self Initiated Research (SAMRC-SIR). | en_US |
| dc.description.uri | https://www.frontiersin.org/journals/genetics | en_US |
| dc.identifier.citation | Kaur, M. & Dlamini, Z. (2022), Editorial: Cholesterol and cancer drug resistance: Molecular, signaling, and therapeutic aspects. Frontiers in Genetics 13:994181. doi: 10.3389/fgene.2022.994181. | en_US |
| dc.identifier.issn | 1664-8021 (online) | |
| dc.identifier.other | 10.3389/fgene.2022.994181 | |
| dc.identifier.uri | https://repository.up.ac.za/handle/2263/88057 | |
| dc.language.iso | en | en_US |
| dc.publisher | Frontiers Media S.A. | en_US |
| dc.rights | © 2022 Kaur and Dlamini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). | en_US |
| dc.subject | Cholesterol | en_US |
| dc.subject | Cancer drug resistance | en_US |
| dc.subject | Molecular pathway | en_US |
| dc.subject | Therapeutic targets | en_US |
| dc.subject | Epithelial-mesenchymal transition (EMT) | en_US |
| dc.title | Editorial : Cholesterol and cancer drug resistance : molecular, signaling, and therapeutic aspects | en_US |
| dc.type | Article | en_US |
